BRAF and metastatic melanoma: Early phase I and II single arm trials suggested that anti-PD-1 plus BRAF inhibitor and MEK inhibitor may be associated with a higher percentage of patients with BRAF V600-mutant metastatic melanoma achieving more durable responses.